analysis of real-world outcomes in patients with b-all receiving tisagenlecleucel
Published 1 year ago • 66 plays • Length 2:18Download video MP4
Download video MP3
Similar videos
-
1:59
real-world outcomes of ide-cel in heavily pre-treated r/r mm
-
1:55
long-term real-world experience of cpx-351 in patients with t-aml and mrc-aml
-
6:09
brexu-cel in adults with r/r b-all: a real-world outcomes collaboration
-
1:44
real-world outcomes of brexu-cel for r/r b-all: evidence from the cibmtr registry
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
3:17
insights into the health-related quality of life of patients with hemophilia
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
2:47
real-world data on the safety of emicizumab in patients with hemophilia a
-
1:08
the real-world safety and efficacy of cpx-351 in patients with aml
-
6:31
the importance of patient perspectives and real-world data
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:45
the importance of real-world data in cll & efficacy of btk and bcl-2 inhibitors in the real world
-
1:17
retrospective real-world study evaluating compassionate use of ponatinib in r/r ph-like all
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
0:45
difference between quality of life & patient-reported outcomes
-
2:22
real-world outcomes following dose reduction of first-line ibrutinib in patients with wm
-
8:34
hct in mds: cell source and conditioning type